Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 04 Dec 2019
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 05 Dec 2019
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).

MicroRNA enrichment in plasma may be indicative of ovarian cancer

29 Sep 2019

Measuring plasma microRNAs (miRNAs) can be a noninvasive diagnostic technique for predicting the development of ovarian cancer, a recent study has found.

Using quantitative reverse transcription polymerase chain reaction, researchers identified putative miRNA markers in plasma samples of 66 participants, of whom 32 had ovarian cancer and 34 were healthy controls. Distant metastasis was reported in 19 patients with the malignancy, while most (n=22) were at menopause.

Five miRNAs were found to be differentially expressed in the ovarian cancer patients: miR-205-5p, miR-145-5p, miR-10a-5p, miR-346 and miR-328-3p. Expression levels for all identified miRNAs were significantly elevated relative to the healthy control counterparts.

Individually, the putative predictive miRNAs had area under curve (AUC) values of 0.681, 0.702, 0.680, 0.737 and 0.700, respectively, as determined by receiver operating characteristic curve analysis. When all five were combined into a panel, the resulting AUC was 0.760 (95 percent CI, 0.691–0.828), suggesting a better predictive value than all individual molecules.

Seeking to identify potential mechanisms of action, researchers then assessed the levels of the identified miRNA molecules in different tissue samples. They found that the levels of miR-145-5p, miR-10a-5p, miR-346 and miR-328-3p were all significantly downregulated in tumour vs normal tissues; expression levels in plasma exosomes, on the other hand, were all significantly increased.

A potential explanation for this was given by Zhao and colleagues in their 2015 paper: “[C]irculating miRNAs were believed to be passively leaked or actively transported from cells during tumorigenesis and packaged into small membranous vesicles or protected by the formation of a protein-miRNA complex, and the miRNAs with low expression levels in tumour tissue might be broken down in tissues and then released into the bloodstream.” [Sci Rep 2015;5:11251]

However, more studies are required to confirm this, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Natalia Reoutova, 21 Nov 2019

Final analysis of the POEMS (Prevention of Early Menopause) study finds that breast cancer (BC) patients treated with the gonadotrophin-releasing hormone agonist (GnRHa) goserelin, in addition to chemotherapy, are more likely to avoid premature menopause and to become pregnant without negatively impacting disease-related outcomes.

Jairia Dela Cruz, 04 Dec 2019
In breast cancer, especially hormone-negative tumours, an ultrasound-guided core biopsy (CNB) is useful for predicting pathologic complete response (pCR) to chemotherapy and may thus help to avoid surgery for some patients, a study has found.
Stephen Padilla, 05 Dec 2019
Circulating miR-155 may be potentially used as a diagnostic and therapeutic monitoring marker in breast cancer, suggests an Indonesian study presented at the 2019 Asia Congress of the European Society for Medical Oncology (ESMO Asia 2019).
Christina Lau, 14 Feb 2019
Progress in the treatment of rare cancers has been named Advance of the Year by the American Society of Clinical Oncology (ASCO).